Bone morphogenetic protein ii (BMp2), a member of the transforming growth factor-β (tgF-β) superfamily, is highly expressed in osteoblasts and is a crucial regulator of osteogenic differentiation. Many observations clearly indicate the high potency of BMp2 as an inducer of osteogenesis, and it may be a novel therapeutic target for diseases associated with bone loss, especially in menopausal and postmenopausal women. to discover new agents that enhance the expression of the mouse BMp2, the authors developed a high-throughput assay to screen a synthetic and natural compound library. the cell-based high-throughput screen was conducted in 96-well plates using the clonal murine calvarial Mc3t3-e1 cells. these cells were stably transfected with mouse BMp2 promoter-luciferase and calibrated with the known antiosteoporosis compound genistein. among 3192 compounds screened, 3 agents (daidzein, formononetin, and 2-acetyldibenzothiophene) were picked up by the high-throughput screening assay, and those compounds were identified as upregulators of BMp2 expression by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. thus, it is demonstrated that this screening model is useful for identifying lead compounds to treat osteoporosis and maintain bone metabolism balance.
INTRODUCTION
B one Morphogenetic proteins (BMps), structurally related to the transforming growth factor-β (tgF-β) superfamily, have diverse physiological functions that play a role in chondrocyte differentiation and/or apoptosis. 1 among BMps, BMp2 has been extensively studied and demonstrated to play an important role in osteoblast differentiation and bone formation. For example, overexpression of BMp2 in osteoblasts was reported to increase osteogenic differentiation of these cells in vitro. 2 and mice with null mutations in BMp2 or BMp2 receptor genes died during early embryogenesis. 3 systemically administered rhBMp2 promotes mesenchymal stem cell (Msc) activity and reverses bone and cartilage loss in osteopenic mice. 4 it has been reported recently that BMp2 genetic variation is a major risk factor for osteoporosis and osteoporotic fractures upon linkage analysis in a large number of extended osteoporosis families in iceland. 5 these observations indicate BMp2, as an inducer of osteogenesis, is likely to be a novel therapeutic target for diseases associated with bone loss and fracture. in this study, a cell-based high-throughput screening (hts) method for BMp2 upregulators was developed. this assay used murine calvarial Mc3t3-e1 cells that were stably transfected with pgl4-Bmp2, a firefly luciferase reporter gene fused downstream of the 5′-flanking promoter region of mouse Bmp2 gene. genistein, an isoflavone that may increase bone formation and decrease bone absorption, 6 is used as a positive control for the optimization and evaluation of the hts assay in 96-well plates. a library of 3192 compounds was screened using the developed assay, and 3 positive compounds were identified, all of which increased promoter activity in a dose-dependent manner. herein we found these compounds stimulate the expression of BMp2 at the level of rna and protein. thus, the approach of screening and validation presented here offers a tool for the discovery of novel BMp2 upregulators.
MATERIALS AND METHODS

Materials
cell culture media and fetal bovine serum (FBs) were obtained from hyclone (logan, ut). g418 and dMso were from amresco (cleveland, oh). sac i and Xho i were the products of taKara Biotechnology co, ltd. (dalian, china), and white-wall, clear-bottom 96-well polystyrene assay plates were purchased from BMg labtech (offenburg, germany). the 6-well and 96-well plates for cell culture were from corning (acton, Ma).
Cell culture
human osteoblast-like cell line Mg63 and murine calvarial Mc3t3-e1 cells were obtained from the cell culture centre, institute of Basic Medical science chinese academy of Medical sciences (Beijing, china). they were grown in minimum essential medium (MeM) or dulbecco's modified eagle's medium (dMeM), respectively, supplemented with 10% heatinactivated FBs at 37 °c in a humidified 5% co 2 incubator.
Reporter plasmid construction
in the -3365bp to -1658bp promoter, there is a retinoic acid-responsive element (rare) located between -2373 and -2316 bp, a sp1 site between -2308 and -2298 bp, a tata promoter sequence between -2155 and -2150 bp, and a transcription start site at nucleotide -2127 bp. the plasmid pcat4.5X with the 5′-flanking promoter region -3365 to -1658 of the mouse Bmp2 gene was kindly provided by prof. Melissa B. rogers (Biochemistry & Molecular Biology, new Jersey Medical school, uMdnJ). after sequence verification, the 1709-bp product was cloned into the pgl4.17-basic vector (promega, Madison, Wi) using saci-Xhoi restriction sites. this constructed vector, designated pgl4-Bmp2, contains mouse Bmp2 promoter region, reporter gene luc2, and neomycin resistance gene. Mc3t3-e1 cells were transfected with pgl4-Bmp2 at 90% confluence using lipofectamine 2000 (invitrogen, carlsbad, ca) according to the manufacturer's instructions. the transfected cells were trypsinized, and then a serial of dilution with dMeM was performed, following a 24-h period of incubation. the selection of stable transfected cells was carried out by treating cells with g418 (1000 µg/ml) in the 96-well plates. after 20 generations of antibiotic selection, single-cell clones with drug resistance were chosen, and the expressed luciferase activity of different single clones was measured using the luciferase assay system (promega). the highest active single clone was designated BMp2-luc-Mc3t3 for the hts assay. this cell line was maintained in culture medium with g418 at 900 µg/ml.
HTS assay
the compound library used for screening in this study is a synthetic and natural library of the institute of Medicinal Biotechnology, chinese academy of Medical sciences, which consists of 734 natural compounds and 2458 synthetic compounds. of the 734 natural compounds in the library, 289 were purchased from the national pharmaceutical engineering center for chinese herbs (nanchang, china), and 145 were from the institute of Medicinal plant development chinese academy of Medical sciences (Beijing, china). 100 microbial products were obtained from Kitasato institute, Japan, and 200 microbial products were isolated from microbial fermentation in our institute. the remainder, 2458 compounds, was synthesized in our institute (2050), china pharmaceutical university (258), and sun yat-sen university (150).
stock compounds were made up in 40 deep 96-well plates at 10 mg/ml in 100% dMso. For each plate, 80 wells contained compound samples, and the remaining 16 wells were negative control wells with pure dMso. compounds were diluted to 1 µg/ml before using. BMp2-luc-Mc3t3 cells were seeded in 96-well plates at 50,000 cells per well in 150 µl culture medium. after an 8-h incubation, the cells at 90% confluence were washed once with phosphate-buffered saline (pBs) and then replaced with 200 µl dMeM, containing 1 µg/ml of various screening samples (80 wells) and 1 µg/ml of positive control genistein (3 wells) and negative control 0.1% dMso (3 wells), respectively. For primary screening, each compound was tested only in singlet. For reassay, each primary positive compound was done in triplicate. after a 24-h incubation at 37 °c, cells were washed with pBs and lysed with cclr (promega), and their relative luminescence units (rlus) were detected using the luciferase assay system (promega).
Real-time quantitative RT-PCR and flow cytometry analysis for BMP2 expression
the Mg63 osteoblast-like cell line, a good model for examining the early stages of human osteoblast differentiation, was used for rna and protein expression analysis to verify the effectiveness of positive compounds on human BMp2 transcription and expression. this is the secondary verification of the hts screening. Mg63 cells at 90% confluence were treated for 24 h with indicated compounds in 6-well plates before each analysis.
For real-time quantitative rt-pcr analysis, total rna was extracted from Mg63 cells using trizol reagent (invitrogen). total cellular rna was analyzed by agarose gel electrophoresis to check the integrity of ribosomal rnas. the rna of negative control, positive control, and screening positive compoundtreated cells were normalized to 100 ng/µl. rna was reverse transcribed using the high capacity cdna reverse transcription Kit (applied Biosystems, Foster city, ca), and the cdna was amplified by the Faststart universal syBr green Master (roche, Basel, switzerland). the number of amplification cycles was optimized to guarantee the measurements within a linear range. 7 the primer pairs used for the amplification of human BMp2 mrna (68 bp) and human β-actin mrna (97 bp) followed the description in roche applied science. the primers are 5′-cggactgcggtctcctaa-3′ and 5′-ggaagcagcaacgctagaag-3′ for Bmp2 and 5′-ccaaccgcgagaagatga-3′ and 5′-ccagaggcgtacagggatag-3′ for β-actin. Quantitative reverse transcriptase pcr was performed using a rotor-gene 3000 realtime pcr machine (corbett research, sydney, australia). expression data were normalized by β-actin levels.
For flow cytometry analysis, cells were washed with pBs and incubated with trypsinogen to detach from the plates at first. the cell suspension was centrifuged (3 min, 800 g), and the obtained pellet was fixed in 4% paraformaldehyde for 40 min at room temperature. second, cells were washed with pBs, resuspended in 500 µl triton-pBs buffer (with 0.2% triton X-100 and 0.5% FBs), and incubated for 10 min on ice. third, cells were carefully pipetted to yield single-cell suspensions, probed with goat igg anti-BMp2 (1:40, r&d systems, Minneapolis, Mn) on ice for 1 h, and followed by 3 washes with pBs. after centrifugation, the cells incubated with Fitcantigoat immunoglobulins (1:100, r&d systems) for 1 h on ice. at the same time, cells were also incubated with isotypematched control primary antibody followed by secondary antibody. last, fluorescence was analyzed using an epics Xl flow cytometer (coulter corporation, Miami, Fl).
Data analysis
the signal-to-noise (s/n) ratio and Z′ value of 96 wellplates were calculated according to the method described by Zhang et al. 8 the activity of negative control 0.1% dMso was defined as the basis for 100% activity. the upregulatory activity of tested compounds was defined as (rlu test compound / rlu negative control ) × 100%. the sample was considered primarily positive when the activity was ≥150%. and a sample, the regulative activity of which was ≥150% at a 95% confidence interval validated in a triplicate reassay, was defined as the validated positive sample. apparent ec 50 values were calculated by using originpro 7.5 software (origen lab, northampton, Ma). the quantitative data were expressed as mean ± standard error. statistical significance of the data was evaluated by student t-test, and p < 0.05 indicated a statistically significant result.
RESULTS
Analysis of the promoter activity of mouse Bmp2 gene
the conservation of BMp2 remarkably exists on both sequence and functional levels in several vertebrate animals. 9,10 critical regulatory elements mediating the expression of BMp2 have been retained throughout evolution, and the promoter regions of the Bmp2 gene are highly conserved between humans and mice. thus, for the primary screening, we used the mouse BMp2 promoter-linked luciferase reporter gene in establishing the hts assay.
the Bmp2 promoter transcriptional activity profile was studied by comparing the activities of 2 types of Mc3t3-e1 cells that were transfected with the promoterless pgl4-basic vector and the reporter vector pgl4-Bmp2. the luciferase reporter assay showed that the ~1709-bp Bmp2 promoter activity was 6-fold higher than that of the promoterless vector (p < 0.001; Fig. 1 , open bars). and after 24 h of genistein treatment on pgl4-Bmp2 cells, the upregulatory activity was over 2-fold compared with the negative control 0.1% dMso (Fig. 1, right  2 columns). these results indicate that the reporter vector was successfully transfected into Mc3t3-e1 cells and with noticeable drug sensitivity.
Cell-based assay optimization
to valuate an assay, one must assess the reproducibility and signal variation at the activity range. s/n ratio, an indication of confidence degree with which a signal can be regarded as real, was chosen as the key parameter to the optimization of selecting conditions. three assay parameters influencing the signal and noise of the cellular reaction, the system solvent, and variations of cell number and incubation time were taken into consideration. BMp2-luc-Mc3t3 cells were further optimized by genistein, a reported BMp2 upregulator. 6 the optimization was focused on getting the appropriate s/n ratio and ensuring time effectiveness of the hts assay. the screening conditions were systematically adjusted to set up acceptable assay while the growing condition of cells was under observation. data were all based on at least 3 independent assay plates, and each was done in triplicate. 1 . the sensitivity of dMso concentration. cells were seeded at 50,000 cells/well and treated by blank control (dMeM) and serial dilution of dMso (0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 5%). after a 24-h incubation, it showed that the assay could tolerate up to 0.5% dMso without apparent loss of luciferase activity (p > 0.05) and cell viability. 2. cell number. cells were seeded from 5000 to 100,000 cells/ well, followed by 24-h treatment of 1 µg/ml genistein and negative control (0.1% dMso). the s/n ratios of 100,000, 50,000, 20,000, 10,000, and 5000 cells/well were 34.3 ± 0.3, 27.8 ± 0.6, 26.7 ± 0.6, 12.3 ± 0.4, and 6.68 ± 0.49, respectively. among them, 50,000 cells/well and 100,000 cells/well both showed high response activities (p < 0.001), and the former was chosen for the hts assay considering time effectiveness and cost saving. 3. incubation time. incubation time was varied from 12 h to 72 h with a 12-h interval. cells were plated at 50,000 cells/ well, followed by incubation in the presence of 1 µg/ml genistein and negative control (0.1% dMso). the s/n ratios of 12, 24, 36, 48, 60, and 72 h were 11.5 ± 0.5, 30.0 ± 0.9, 32.9 ± 1.4, 12.0 ± 1.1, 27.3 ± 1.1, and 41.29 ± 0.9, respectively. at 48 and 60 h, cells had high response activities with p < 0.001; at 24 and 36 h, the available response activities were found with p < 0.01. the 24-h incubation was chosen by finally considering the combination of s/n ratio and time effectiveness.
these results suggested that parallel tests should be conducted in the same conditions because variations in dMso concentrations, cell counts, and incubation time would all have effects on the assay performance.
HTS analysis and characterization of positive compounds
the Z′ factor, a characteristic parameter for the quality of the assay itself without intervention of test compounds, was chosen for evaluating reproducibility and quality of overall assays because it is sensitive to the data variability as well as the signal dynamic range. 8 the overall Z′ value for each plate in a total of 40 plates was 0.69 ± 0.03, indicating the robustness of this hts assay. Five primary positive samples (0.15%) showed greater than 150% regulatory activity, and 3 of them were confirmed by reassay. the dose-response curve for each compound was tested in 3 separate experiments, and each was done in triplicate. chemical structures of each compound and the ec 50 of BMp2 regulatory activities illustrated from their dose-response curve are summarized in Table 1 .
isoflavones are a class of phytoestrogens, among which genistein and daidzein were reported to present biological activity of BMp2 stimulation. 6, 11 genistein, on which the molecular mechanism of phytoestrogens was concentrated, was reported to concurrently activate both estrogen receptors (ers) and peroxisome proliferator-activated receptors (ppars). 12, 13 Both ers and ppars could interact with sp1 and rare, which exist in our constructed vector, to promote Bmp2 expression. hence, genistein was chosen to be the positive control for hts screening, and its BMp2 stimulation activity was consistent with previous description. daidzein was picked up in a random hts assay from our compound library, which proves the reliability of the model. Formononetin and 2-acetyldibenzothiophen (aBt) are first reported as novel BMp2 upregulators.
Genistein, daidzein, formononetin, and 2-ABT induce BMP2 mRNA and protein expression in MG63 cells
although in vitro mouse Bmp2 promoter is easier to manipulate and transfect than that of human Bmp2 promoter, the secondary verification of the indicated compounds on human BMp2 expression is crucial. thus, BMp2 stimulation activities of the indicated compounds on human rna and protein levels were confirmed in the human osteogenetic cell line Mg63 in our research.
Quantitative rt-pcr analysis ( Fig. 2A) and flow cytometry analysis (Fig. 2B) showed that genistein and the 3 positive compounds significantly stimulated the mrna and protein expression with the concentrations of 5 µM and 10 µM after a 24-h treatment. regarding rna levels, genistein, daidzein, and 2-aBt reached 3. 2.3-fold at 10 µM, respectively, whereas formononetin showed no significant difference among different concentrations of 1 µM, 5 µM, and 10 µM, all above 2.0-fold. in contrast, 2-aBt affected protein levels maximally at 5 µM (2.1-fold), with lower protein expression at both 1 µM and 10 µM.
SUMMARY
a novel hts assay for the identification of upregulators of BMp2 was established in this study. three positive agents were picked from 3192 compounds, and their biological effect on human BMp2 was confirmed. the effect of inhibition on bone resorption and stimulation on bone formation of BMp2 has made this molecule an important target for preventing or even reversing osteoporosis. using this assay for further hts may promote the discovery of novel pharmaceutical agents and also help to unravel other functions of BMp2 and its pathways. 
